ZIC1 is a putative tumor suppressor in thyroid cancer by modulating major signaling pathways and transcription factor FOXO3a

Journal of Clinical Endocrinology and Metabolism

Volumn 99, Issue 7, 2014, Pages

  Qiang, Wei ^a   Zhao, Yuan ^b   Yang, Qi ^a   Liu, Wei ^a   Guan, Haixia ^c   Lv, Siqing ^a   Ji, Meiju ^a   Shi, Bingyin ^a   Hou, Peng ^a  

^a MEDICAL SCHOOL OF XI AN JIAOTONG UNIVERSITY   (China)

^b SHAANXI PROVINCIAL PEOPLE S HOSPITAL   (China)

^c CHINA MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; RAF PROTEIN; RAS PROTEIN; TRANSCRIPTION FACTOR FKHRL1;

APOPTOSIS; ARTICLE; CANCER CELL; CANCER CELL LINE; CANCER TISSUE; CARCINOGENESIS; CELL CYCLE; CELL CYCLE ARREST; CELL INVASION ASSAY; CELL MIGRATION ASSAY; CELL PROLIFERATION; COLONY FORMATION; CONTROLLED STUDY; DOWN REGULATION; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; LYMPH NODE METASTASIS; METHYLATION; MOLECULAR MECHANICS; PRIORITY JOURNAL; PROMOTER REGION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; THYROID CARCINOMA; TUMOR SUPPRESSOR GENE; ZIC1 GENE;

APOPTOSIS; CARCINOMA; CELL PROLIFERATION; DNA METHYLATION; FORKHEAD TRANSCRIPTION FACTORS; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE SILENCING; GENES, TUMOR SUPPRESSOR; HUMANS; NEOPLASM INVASIVENESS; PROMOTER REGIONS, GENETIC; SIGNAL TRANSDUCTION; THYROID NEOPLASMS; TRANSCRIPTION FACTORS; TUMOR CELLS, CULTURED;

EID: 84904054609     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2013-3729     Document Type: Article

References (37)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61:69-90.
2. Burns WR, Zeiger MA. Differentiated thyroid cancer. Semin Oncol. 2010;37:557-566.
3. Xing M. Molecular pathogenesis and mechanisms of thyroid cancer. Nat Rev Cancer. 2012;13:184-199.
4. Cornett WR, Sharma AK, Day TA, et al. Anaplastic thyroid carcinoma: an overview. Curr Oncol Rep. 2007;9:152-158. (Pubitemid 46332389)
5. Nikiforov YE, Nikiforova MN. Molecular genetics and diagnosis of thyroid cancer. Nat Rev Endocrinol. 2011;7:569-580.
6. Xing M. Gene methylation in thyroid tumorigenesis. Endocrinology. 2007;148:948-953.
7. Jones PA, Baylin SB. The fundamental role of epigenetic events in cancer. Nat Rev Genet. 2002;3:415-428. (Pubitemid 34587077)
8. Baylin SB, Jones PA. A decade of exploring the cancer epigenome - biological and translational implications. Nat Rev Cancer. 2011;11:726-734.
9. Merzdorf CS. Emerging roles for zic genes in early development. Dev Dyn. 2007;236:922-940. (Pubitemid 46641334)
10. Aruga J. The role of Zic genes in neural development. Mol Cell Neurosci. 2004;26:205-221. (Pubitemid 38781079)
11. Grinberg I, Millen KJ. The ZIC gene family in development and disease. Clin Genet. 2005;67:290-296. (Pubitemid 40424825)
12. Yokota N, Aruga J, Takai S, Yamada K, et al. Predominant expression of human zic in cerebellar granule cell lineage and medulloblastoma. Cancer Res. 1996;56:377-383. (Pubitemid 26026368)
13. Aruga J, Nozaki Y, Hatayama M, Odaka YS, Yokota N. Expression of ZIC family genes in meningiomas and other brain tumors. BMC Cancer. 2010;10:79.
14. Brill E, Gobble R, Angeles C, et al. ZIC1 overexpression is oncogenic in liposarcoma. Cancer Res. 2010;70:6891-6901.
15. Wang LJ, Jin HC, Wang X, Lam EK, et al. ZIC1 is downregulated through promoter hypermethylation in gastric cancer. Biochem Biophys Res Commun. 2009;379:959-963.
16. Gan L, Chen S, Zhong J, et al. ZIC1 is downregulated through promoter hypermethylation, and functions as a tumor suppressor gene in colorectal cancer. PLoS One. 2011;6:e16916.
17. Rodríguez-Rodero S, Fernández AF, Fernández-Morera JL, et al. DNA methylation signatures identify biologically distinct thyroid cancer subtypes. J Clin Endocrinol Metab. 2013;98:2811-2821.
18. Halaschek-Wiener J, Wacheck V, Kloog Y, Jansen B. Ras inhibition leads to transcriptional activation of p53 and down-regulation of Mdm2: two mechanisms that cooperatively increase p53 function in colon cancer cells. Cell Signal. 2004;16:1319-1327. (Pubitemid 39165460)
19. Mayo LD, Donner DB. A phosphatidylinositol 3-kinase/Akt pathway promotes translocation of Mdm2 from the cytoplasm to the nucleus. Proc Natl Acad Sci U S A. 2001;98:11598-11603. (Pubitemid 32928774)
20. Zhou BP, Liao Y, Xia W, Zou Y, Spohn B, Hung MC. HER-2/neu induces p53 ubiquitination via Akt-mediated MDM2 phosphorylation. Nat Cell Biol. 2001;973-982. (Pubitemid 34428742)
21. Ogawara Y, Kishishita S, Obata T, et al. Akt enhances Mdm2-mediated ubiquitination and degradation of p53. J Biol Chem. 2002;277:21843-21850. (Pubitemid 34952337)
22. Nevins JR. The Rb/E2F pathway and cancer. Hum Mol Genet. 2001;10:699-703. (Pubitemid 32331578)
23. Yang JY, Hung MC. A new fork for clinical application: targeting forkhead transcription factors in cancer. Clin Cancer Res. 2009;15:752-757.
24. Greer EL, Brunet A. FOXO transcription factors at the interface between longevity and tumor suppression. Oncogene. 2005;24:7410-7425. (Pubitemid 41637981)
25. Zhang X, Tang N, Hadden TJ, Rishi AK. Akt, FoxO and regulation of apoptosis. Biochim Biophys Acta. 2011;1813:1978-1986.
26. Cornish EJ, Hassan SM, Martin JD, Li S, Merzdorf CS. A microarray screen for direct targets of Zic1 identifies an aquaporin gene, aqp-3b, expressed in the neural folds. Dev Dyn. 2009;238:1179-1194.
27. Yang JY, Zong CS, Xia W, et al. ERK promotes tumorigenesis by inhibiting FOXO3a via MDM2-mediated degradation. Nat Cell Biol. 2008;10:138-148. (Pubitemid 351194043)
28. Larue L, Bellacosa A. Epithelial-mesenchymal transition in development and cancer: role of phosphatidylinositol 3′ kinase/AKT pathways. Oncogene. 2005;24:7443-7454. (Pubitemid 41637984)
29. Weidinger C, Krause K, Klagge A, Karger S, Fuhrer D. Forkhead box-O transcription factor: critical conductors of cancer's fate. Endocr Relat Cancer. 2008;15:917-929.
30. Fagin JA. Tumorsuppressor genes inhumanthyroid neoplasms: p53 mutations are associated undifferentiated thyroid cancers. J Endocrinol Invest. 1995;18:140-142.
31. Karger S, Weidinger C, Krause K, et al. FOXO3a: a novel player in thyroid carcinogenesis? Endocr Relat Cancer. 2009;16:189-199.
32. Yang JY, Hung MC. Deciphering the role of forkhead transcription factors in cancer therapy. Curr Drug Targets. 2011;12:1284-1290.
33. Belguise K, Guo S, Sonenshein GE. Activation of FOXO3a by the green tea polyphenol epigallocatechin-3-gallate induces estrogen receptor alpha expression reversing invasive phenotype of breast cancer cells. Cancer Res. 2007;67:5763-5770. (Pubitemid 46985009)
34. Shiota M, Song Y, Yokomizo A, et al. Foxo3a suppression of urothelial cancer invasiveness through Twist1, Y-box-binding protein 1, and E-cadherin regulation. Clin Cancer Res. 2010;16:5654-5663.
35. Fenouille N, Tichet M, Dufies M, et al. The epithelial-mesenchymal transition (EMT) regulatory factor SLUG (SNAI2) is a downstream target of SPARC and AKT in promoting melanoma cell invasion. PLoS One. 2012;7:e40378.
36. Shih JY, Yang PC. The EMT regulator slug and lung carcinogenesis. Carcinogenesis. 2011;32:1299-1304.
37. Stetler-Stevenson WG. The role of matrix metalloproteinases in tumor invasion, metastasis, and angiogenesis. Surg Oncol Clin N Am. 2001;10:383-392.